Trust Company
ADMA icon

Trust Company’s ADMA Biologics ADMA Stock Holding History

Trust Company’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$160 Hold
16
– – ﹤0.01% 896
2026
Q2 		$134 Hold
16
– – ﹤0.01% 893
2026
Q1 		$144 Hold
16
– – ﹤0.01% 883
2025
Q4 		$292 Buy
+16
New +$270 ﹤0.01% 826

Other funds holding ADMA

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

Trust Company's ADMA Position: Q3 2026 in Review

Trust Company held its ADMA Biologics (ADMA) position steady in Q3 2026 at 16 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Trust Company first reported a position in ADMA in Q4 2025 and has held it in 4 quarters since. The position peaked at $292 in Q4 2025. 184 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Trust Company held 16 shares of ADMA Biologics worth $160 as of Q3 2026.
  • Trust Company left its ADMA Biologics share count unchanged in Q3 2026.
  • ADMA Biologics made up ﹤0.01% of Trust Company's portfolio in Q3 2026, its #896 holding.
  • Trust Company first reported a position in ADMA Biologics in Q4 2025 and has held it in 4 quarters since.
  • Trust Company's ADMA Biologics position peaked at $292 in Q4 2025.
  • 184 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Trust Company's 13F filing for Q3 2026, filed 9 Oct 2026.